Transcriptome profiling of single prostate cancer cells in the castrate setting

Research output: Contribution to conferenceAbstractOtherpeer-review

Abstract

Androgen withdrawal is the standard of care for men with metastatic prostate cancer. While all patients initially respond, resistance is inevitable and lethal castration-resistant prostate cancer ensues. Using patient-derived xenografts (PDX) of localized tumors, we have identified a subpopulation of castration-tolerant prostate cancer cells that survive following castration. Identifying the unique biologic characteristics of these cells is essential in determining their role in tumor progression and potential to be targeted by therapeutic agents. To study the genomic features of castrate-tolerant cells, we enriched for prostate cancer cells from PDXs using FACS and subjected them to single-cell isolation and RNA seq. We efficiently captured and sequenced >50 cells from pre- and post-castration PDXs using the Fluidigm C1 platform. Sequencing of isolated single cells was performed using the Illumina HiSeq in rapid mode with 50 bp fragment sequencing chemistry (3 million reads/cell). Multidimensional scaling showed that the response to castration is not uniform in all human cells. A unique gene set was identified in intact versus castrate-tolerant cells; we identified distinct changes in energy metabolism, including suppression of ATP production to aid cell survival. We also detected consistent upregulation of the retinoic acid signaling pathway, involving upregulation of CRABP2 and RARRES3 expression in castrate-tolerant cells. This is the first study to report on gene expression in single human prostate cells and revealed novel endocrine-related changes prior to and following androgen deprivation. Our data suggest that further and/or alternative hormone suppression may be effective in targeting castration-tolerant prostate cancer cells.
Original languageEnglish
Number of pages1
DOIs
Publication statusPublished - Jul 2018
EventAnnual Meeting of the American-Association-for-Cancer-Research (AACR) 2018 - Chicago, United States of America
Duration: 14 Apr 201818 Apr 2018

Conference

ConferenceAnnual Meeting of the American-Association-for-Cancer-Research (AACR) 2018
CountryUnited States of America
CityChicago
Period14/04/1818/04/18

Cite this

Clark, Ashlee ; Nim, Hieu ; Lister, Natalie ; Frydenberg, Mark ; Lawrence, Mitchell ; Risbridger, Gail ; Taylor, Renea. / Transcriptome profiling of single prostate cancer cells in the castrate setting. Abstract from Annual Meeting of the American-Association-for-Cancer-Research (AACR) 2018, Chicago, United States of America.1 p.
@conference{2da11f27c82d47fe8860f0e508c40acb,
title = "Transcriptome profiling of single prostate cancer cells in the castrate setting",
abstract = "Androgen withdrawal is the standard of care for men with metastatic prostate cancer. While all patients initially respond, resistance is inevitable and lethal castration-resistant prostate cancer ensues. Using patient-derived xenografts (PDX) of localized tumors, we have identified a subpopulation of castration-tolerant prostate cancer cells that survive following castration. Identifying the unique biologic characteristics of these cells is essential in determining their role in tumor progression and potential to be targeted by therapeutic agents. To study the genomic features of castrate-tolerant cells, we enriched for prostate cancer cells from PDXs using FACS and subjected them to single-cell isolation and RNA seq. We efficiently captured and sequenced >50 cells from pre- and post-castration PDXs using the Fluidigm C1 platform. Sequencing of isolated single cells was performed using the Illumina HiSeq in rapid mode with 50 bp fragment sequencing chemistry (3 million reads/cell). Multidimensional scaling showed that the response to castration is not uniform in all human cells. A unique gene set was identified in intact versus castrate-tolerant cells; we identified distinct changes in energy metabolism, including suppression of ATP production to aid cell survival. We also detected consistent upregulation of the retinoic acid signaling pathway, involving upregulation of CRABP2 and RARRES3 expression in castrate-tolerant cells. This is the first study to report on gene expression in single human prostate cells and revealed novel endocrine-related changes prior to and following androgen deprivation. Our data suggest that further and/or alternative hormone suppression may be effective in targeting castration-tolerant prostate cancer cells.",
author = "Ashlee Clark and Hieu Nim and Natalie Lister and Mark Frydenberg and Mitchell Lawrence and Gail Risbridger and Renea Taylor",
year = "2018",
month = "7",
doi = "10.1158/1538-7445.AM2018-5234",
language = "English",
note = "Annual Meeting of the American-Association-for-Cancer-Research (AACR) 2018 ; Conference date: 14-04-2018 Through 18-04-2018",

}

Clark, A, Nim, H, Lister, N, Frydenberg, M, Lawrence, M, Risbridger, G & Taylor, R 2018, 'Transcriptome profiling of single prostate cancer cells in the castrate setting' Annual Meeting of the American-Association-for-Cancer-Research (AACR) 2018, Chicago, United States of America, 14/04/18 - 18/04/18, . https://doi.org/10.1158/1538-7445.AM2018-5234

Transcriptome profiling of single prostate cancer cells in the castrate setting. / Clark, Ashlee; Nim, Hieu; Lister, Natalie; Frydenberg, Mark; Lawrence, Mitchell; Risbridger, Gail; Taylor, Renea.

2018. Abstract from Annual Meeting of the American-Association-for-Cancer-Research (AACR) 2018, Chicago, United States of America.

Research output: Contribution to conferenceAbstractOtherpeer-review

TY - CONF

T1 - Transcriptome profiling of single prostate cancer cells in the castrate setting

AU - Clark, Ashlee

AU - Nim, Hieu

AU - Lister, Natalie

AU - Frydenberg, Mark

AU - Lawrence, Mitchell

AU - Risbridger, Gail

AU - Taylor, Renea

PY - 2018/7

Y1 - 2018/7

N2 - Androgen withdrawal is the standard of care for men with metastatic prostate cancer. While all patients initially respond, resistance is inevitable and lethal castration-resistant prostate cancer ensues. Using patient-derived xenografts (PDX) of localized tumors, we have identified a subpopulation of castration-tolerant prostate cancer cells that survive following castration. Identifying the unique biologic characteristics of these cells is essential in determining their role in tumor progression and potential to be targeted by therapeutic agents. To study the genomic features of castrate-tolerant cells, we enriched for prostate cancer cells from PDXs using FACS and subjected them to single-cell isolation and RNA seq. We efficiently captured and sequenced >50 cells from pre- and post-castration PDXs using the Fluidigm C1 platform. Sequencing of isolated single cells was performed using the Illumina HiSeq in rapid mode with 50 bp fragment sequencing chemistry (3 million reads/cell). Multidimensional scaling showed that the response to castration is not uniform in all human cells. A unique gene set was identified in intact versus castrate-tolerant cells; we identified distinct changes in energy metabolism, including suppression of ATP production to aid cell survival. We also detected consistent upregulation of the retinoic acid signaling pathway, involving upregulation of CRABP2 and RARRES3 expression in castrate-tolerant cells. This is the first study to report on gene expression in single human prostate cells and revealed novel endocrine-related changes prior to and following androgen deprivation. Our data suggest that further and/or alternative hormone suppression may be effective in targeting castration-tolerant prostate cancer cells.

AB - Androgen withdrawal is the standard of care for men with metastatic prostate cancer. While all patients initially respond, resistance is inevitable and lethal castration-resistant prostate cancer ensues. Using patient-derived xenografts (PDX) of localized tumors, we have identified a subpopulation of castration-tolerant prostate cancer cells that survive following castration. Identifying the unique biologic characteristics of these cells is essential in determining their role in tumor progression and potential to be targeted by therapeutic agents. To study the genomic features of castrate-tolerant cells, we enriched for prostate cancer cells from PDXs using FACS and subjected them to single-cell isolation and RNA seq. We efficiently captured and sequenced >50 cells from pre- and post-castration PDXs using the Fluidigm C1 platform. Sequencing of isolated single cells was performed using the Illumina HiSeq in rapid mode with 50 bp fragment sequencing chemistry (3 million reads/cell). Multidimensional scaling showed that the response to castration is not uniform in all human cells. A unique gene set was identified in intact versus castrate-tolerant cells; we identified distinct changes in energy metabolism, including suppression of ATP production to aid cell survival. We also detected consistent upregulation of the retinoic acid signaling pathway, involving upregulation of CRABP2 and RARRES3 expression in castrate-tolerant cells. This is the first study to report on gene expression in single human prostate cells and revealed novel endocrine-related changes prior to and following androgen deprivation. Our data suggest that further and/or alternative hormone suppression may be effective in targeting castration-tolerant prostate cancer cells.

U2 - 10.1158/1538-7445.AM2018-5234

DO - 10.1158/1538-7445.AM2018-5234

M3 - Abstract

ER -

Clark A, Nim H, Lister N, Frydenberg M, Lawrence M, Risbridger G et al. Transcriptome profiling of single prostate cancer cells in the castrate setting. 2018. Abstract from Annual Meeting of the American-Association-for-Cancer-Research (AACR) 2018, Chicago, United States of America. https://doi.org/10.1158/1538-7445.AM2018-5234